July 28, 2021 -- 10x Genomics and Bio-Rad Laboratories have settled their legal dispute and signed a global settlement and cross-license agreement.
According to the deal and for the life of the licensed patents, each company received a nonexclusive, worldwide, royalty-bearing license to develop products and services related to single-cell analysis, 10x Genomics said. Products related to spatial analysis and in situ analysis are excluded from the cross license as are digital polymerase chain reaction products from 10x Genomics.
The agreement settles all outstanding litigation and other proceedings between the two companies across all global jurisdictions. It also dismisses all infringement claims with prejudice, according to 10x Genomics. Both parties have agreed that each firm's patents are owned by each respective company.